Marker Therapeutics Inc (MRKR)

$1.33 -0.02 (-1.48%)
Market Cap 22.18M
Revenue (ttm) 6.59M
Net Income (ttm) -10.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.82%
Debt to Equity Ratio 0.00
Volume 79,100
Avg Vol 340,956
Day's Range N/A - N/A
Shares Out 16.67M
Stochastic %K 4%
Beta 1.42
Analysts Strong Sell
Price Target $9.03

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 400 6400
Address:
2450 Holcombe Blvd, MS: BCM251, Houston, United States
TitusPullo1964
TitusPullo1964 Mar. 12 at 2:41 PM
$MRKR At Boersenplatz Gettex, time today Europe time 3:34 p.m. rate 1.48 dollars
0 · Reply
TitusPullo1964
TitusPullo1964 Mar. 12 at 8:20 AM
$MRKR remember! strong Phase I APOLLO data for its lead T cell therapy MT-601. MT-601 resulted in approximately 66% response in NHL and 78% durable response in Hodgkin's lymphoma. MRKR has further developed MT-601 for dose expansion, secured funding and production support and expects further data in the first half of 2026.
0 · Reply
itsMeRich
itsMeRich Mar. 11 at 9:52 PM
$MRKR companies like Immunitybio , appear to be ahead of Marker, with New Killer cell treatment, FDA approval, and over $100M in sales their 1st year. Marker has been dragging this out for way too long…. And it’s apparent, that many are losing interest.
0 · Reply
BCa1
BCa1 Mar. 11 at 4:10 PM
$MRKR Has anyone read the proposals for the annual meeting? Proposal 3 to increase shares from. 30 to 130 million seems a little excessive. Any thoughts from others would be appreciated. Also they want to restrict the votes required to pass an amendment to the majority of voters present for the proposal. Normal procedure requires majority based on actual number of shares.
2 · Reply
itsMeRich
itsMeRich Mar. 9 at 2:36 PM
$MRKR amazed that this has held up pretty well so far….. something must be brewing.
0 · Reply
itsMeRich
itsMeRich Mar. 4 at 4:17 PM
$MRKR when can we expect the next catalyst?
0 · Reply
TitusPullo1964
TitusPullo1964 Mar. 4 at 4:11 PM
$MRKR
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Mar. 3 at 4:55 PM
$MRKR
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 2:20 PM
$MRKR Current Stock Price: $1.49
0 · Reply
Braggs91
Braggs91 Feb. 27 at 3:20 PM
$MRKR this looks to be highly manipulated. The price chart is either vertical, 90 or 45 degree angles, all perfectly linear. Not natural zig-zagging. Looks like it is controlled by trading bots.
2 · Reply
Latest News on MRKR
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 8:00 AM EST - 25 days ago

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Jan 5, 2026, 7:00 AM EST - 2 months ago

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 7:00 AM EST - 4 months ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 5, 2025, 7:30 AM EST - 4 months ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Nov 3, 2025, 9:15 AM EST - 4 months ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Oct 6, 2025, 7:30 AM EDT - 5 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 7 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Aug 26, 2025, 12:34 PM EDT - 7 months ago

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:00 AM EDT - 8 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Jun 17, 2025, 8:00 AM EDT - 9 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 10 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025, 8:00 AM EDT - 10 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Mar 31, 2025, 8:45 AM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 5:45 PM EDT - 2 years ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 22, 2024, 12:30 PM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 31, 2023, 6:30 AM EDT - 3 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 8, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

May 1, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:10 AM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

TitusPullo1964
TitusPullo1964 Mar. 12 at 2:41 PM
$MRKR At Boersenplatz Gettex, time today Europe time 3:34 p.m. rate 1.48 dollars
0 · Reply
TitusPullo1964
TitusPullo1964 Mar. 12 at 8:20 AM
$MRKR remember! strong Phase I APOLLO data for its lead T cell therapy MT-601. MT-601 resulted in approximately 66% response in NHL and 78% durable response in Hodgkin's lymphoma. MRKR has further developed MT-601 for dose expansion, secured funding and production support and expects further data in the first half of 2026.
0 · Reply
itsMeRich
itsMeRich Mar. 11 at 9:52 PM
$MRKR companies like Immunitybio , appear to be ahead of Marker, with New Killer cell treatment, FDA approval, and over $100M in sales their 1st year. Marker has been dragging this out for way too long…. And it’s apparent, that many are losing interest.
0 · Reply
BCa1
BCa1 Mar. 11 at 4:10 PM
$MRKR Has anyone read the proposals for the annual meeting? Proposal 3 to increase shares from. 30 to 130 million seems a little excessive. Any thoughts from others would be appreciated. Also they want to restrict the votes required to pass an amendment to the majority of voters present for the proposal. Normal procedure requires majority based on actual number of shares.
2 · Reply
itsMeRich
itsMeRich Mar. 9 at 2:36 PM
$MRKR amazed that this has held up pretty well so far….. something must be brewing.
0 · Reply
itsMeRich
itsMeRich Mar. 4 at 4:17 PM
$MRKR when can we expect the next catalyst?
0 · Reply
TitusPullo1964
TitusPullo1964 Mar. 4 at 4:11 PM
$MRKR
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Mar. 3 at 4:55 PM
$MRKR
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 2:20 PM
$MRKR Current Stock Price: $1.49
0 · Reply
Braggs91
Braggs91 Feb. 27 at 3:20 PM
$MRKR this looks to be highly manipulated. The price chart is either vertical, 90 or 45 degree angles, all perfectly linear. Not natural zig-zagging. Looks like it is controlled by trading bots.
2 · Reply
Trak2
Trak2 Feb. 25 at 9:46 PM
$MRKR did marker present anything today? Or is this tomorrow? greatly appreciate any information out there. Thank you.
0 · Reply
WhereAmIGoing
WhereAmIGoing Feb. 25 at 2:10 AM
$MRKR back over my average. Ditched a few JIC. This stock can’t be trusted.
0 · Reply
Drugtrade
Drugtrade Feb. 24 at 7:10 PM
$MRKR got lucky here since following.. sold over2. Red on rebuy, will trade over that price. Building core pos here
0 · Reply
itsMeRich
itsMeRich Feb. 24 at 7:06 PM
$MRKR good afternoon Marker…. Nice to see you alive.
0 · Reply
Luzaich1
Luzaich1 Feb. 22 at 5:20 PM
$MRKR. I was wondering why Alyeska LP did not report shares this quarter, they had a 13G on 11/14/25 -1.280 m shares Any ideas TIA
1 · Reply
Trak2
Trak2 Feb. 18 at 5:40 PM
$MRKR let’s hope their is a update on trial
0 · Reply
tradingviewcyp
tradingviewcyp Feb. 18 at 3:22 PM
$MRKR During the conference, Dr. Vera and Marker’s management team will conduct one-on-one meetings with registered investors to discuss the Company’s progress across its Multi-Antigen Recognizing (MAR) T cell platform
0 · Reply
tradingviewcyp
tradingviewcyp Feb. 18 at 3:03 PM
$MRKR 30 minutes, no change. First time for this stock, interesting.
0 · Reply
PortfolioProvenance
PortfolioProvenance Feb. 17 at 1:12 PM
$MRKR Pre-revenue biotech; early-stage.
0 · Reply
Trak2
Trak2 Feb. 16 at 5:31 AM
$MRKR i’m thinking a clinical data read out and partnership announcement, let’s hope🙏🏼🙏🏼
0 · Reply
BCa1
BCa1 Feb. 14 at 4:20 PM
$MRKR Okay does anyone have any thoughts as to why the annual meeting has moved to May? Please be entertaining or have good ideas based on dates. Will this give them time to present data in the trials. Partner up....
1 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Feb. 12 at 6:14 PM
$MRKR She ran on Baylor's data,held within the trendline against market headwinds all the while looking at Vera with the expression - do something u fcxking loser!
0 · Reply